PICO Portalanswers from OpenAlex & ORCID
Jean‐Yves Douillard
ResearcherPublications, citations & collaboration network
Jean‐Yves Douillard is a researcher indexed in PICO Portal from OpenAlex & ORCID.
How many works does Jean‐Yves Douillard have?
PICO Portalindexed works
Jean‐Yves Douillard has 383 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jean‐Yves Douillard have?
PICO Portalcitation count
Jean‐Yves Douillard has 33,552 citations in the OpenAlex counts PICO Portal stores.
What is the h-index of Jean‐Yves Douillard?
PICO Portalh-index
Jean‐Yves Douillard has an h-index of 69 in OpenAlex.
What is the i10-index of Jean‐Yves Douillard?
PICO Portali10-index
Jean‐Yves Douillard has an i10-index of 173 in OpenAlex.
What is the ORCID of Jean‐Yves Douillard?
PICO Portalorcid
The ORCID for Jean‐Yves Douillard is on the source record.
What is the OpenAlex record for Jean‐Yves Douillard?
PICO Portalopenalex
The OpenAlex for Jean‐Yves Douillard is on the source record.
What are the most-cited papers on Jean‐Yves Douillard?
PICO Portalmost cited works
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
Martin Reck, R. Kaiser, Anders Mellemgaard, Jean‐Yves Douillard, С. В. Орлов, Maciej Krzakowski, Joachim von Pawel, Maya Gottfried, Igor Bondarenko, Meilin Liao, Claudia-Nanette Gann, José Barrueco, Birgit Gaschler‐Markefski, Silvia Novello
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Takayuki Yoshino, Dirk Arnold, Hiroya Taniguchi, George Pentheroudakis, Kentaro Yamazaki, Rui‐Hua Xu, Tae‐Woo Kim, Muhammad Ismail, Iain Tan, Kun‐Huei Yeh, Axel Grothey, S. Zhang, Joong Bae Ahn, M.Y. Mastura, Dawn Q. Chong, Liqun Chen, Scott Kopetz, Takako Eguchi-Nakajima, Hiromichi Ebi, Atsushi Ohtsu, Andrés Cervantes, Kei Muro, Josep Tabernero, Hironobu Minami, Fortunato Ciardiello, Jean‐Yves Douillard
Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer
Primo N. Lara, Jean‐Yves Douillard, Kazuhiko Nakagawa, Joachim von Pawel, Mark J. McKeage, István Albert, György Losonczy, Martin Reck, Dae Seog Heo, Xiaolin Fan, Abderrahim Fandi, Giorgio V. Scagliotti